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Anorexia and weight loss are part of the wasting syndrome of late-stage cancer, 
are a major cause of morbidity and mortality in cancer, and are thought to be 
cytokine mediated. Macrophage inhibitory cytokine-1 (MIC-1) is produced by 
many cancers. Examination of sera from individuals with advanced prostate 
cancer showed a direct relationship between MIC-1 abundance and cancer-
associated weight loss. In mice with xenografted prostate tumors, elevated MIC-
1 levels were also associated with marked weight, fat and lean tissue loss that 
was mediated by decreased food intake and was reversed by administration of 
antibody to MIC-1. Additionally, normal mice given systemic MIC-1 and 
transgenic mice overexpressing MIC-1 showed hypophagia and reduced body 
weight. MIC-1 mediates its effects by central mechanisms that implicate the 
hypothalamic transforming growth factor-β receptor II, extracellular signal–
regulated kinases 1 and 2, signal transducer and activator of transcription-3, 
neuropeptide Y and pro-opiomelanocortin. Thus, MIC-1 is a newly defined central 
regulator of appetite and a potential target for the treatment of both cancer 
anorexia and weight loss, as well as of obesity. 
Weight and appetite control are complex, incompletely characterized processes whose 
dysregulation can lead to obesity or anorexia. In late-stage cancer, it is believed that 
tumor- or stromal cell–derived molecules disturb the stringent control of appetite and 
weight control, leading to wasting, debility and often death1, 2, 3, 4, 5, 6. Interleukin-6 (IL-6) 
has been considered the likeliest etiological agent of anorexia and cachexia, although 
several cytokines have been implicated in this process. 
 MIC-1, also called GDF-15, PLAB, PDF or NAG-1, is a transforming growth factor-β 
(TGF-β) superfamily protein. It is not expressed under basal conditions but may be 
induced by inflammation, injury or malignancy7, 8, 9, 10, 11, 12, 13. MIC-1 is overexpressed in 
many cancers, including those of the prostate, colon, pancreas and breast14. In individuals 
with advanced cancer, serum MIC-1 can rise from a mean of 0.45 ng/ml to 5–50 ng/ml or 
higher. Individual tumors vary in the amount of MIC-1 they secrete because of differences 
in expression level and variation in the processing of mature MIC-1 by pro-convertases11. 
 Here we examine the consequences of elevated circulating levels of MIC-1 and 
show that tumors overexpressing MIC-1 induce anorexia, which can be reversed by 
administration of antibodies to MIC-1 and mimicked by injection of recombinant MIC-1. We 
further show a direct correlation between serum MIC-1 levels and weight loss in individuals 
with advanced prostate cancer or chronic renal failure. In addition, we show that MIC-1 
modulates neuronal pathways important in the regulation of appetite and energy 
homeostasis. 
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RESULTS 
 
MIC-1 induces rapid weight loss reversed by antibodies to MIC-1 
To understand the effects of systemic overexpression of MIC-1, we stably transfected the 
human prostate cancer cell line DU145 with human MIC-1 (MIC-1) constructs and injected 
these cells subcutaneously (s.c.) into the flanks of nude mice to establish xenografted 
tumors11. Mice were weighed regularly and killed after 6 weeks. Those with elevated 
amounts of tumor-derived human MIC-1 progressively lost weight (Figs. 1 and 2a,b). Mice 
with low serum levels of tumor-derived human MIC-1 (0–1,500 pg/ml), similar to levels 
found in normal humans, gained about 19% body weight, consistent with the young age of 
these mice (Fig. 1a). Mice with moderately elevated MIC-1 (1,501–8,500 pg/ml) lost 3% 
of body weight, and those with markedly elevated MIC-1 (>8,500 pg/ml) lost 28% of body 
weight (Fig. 1a). As mice with control tumors continued to gain weight, the net relative 
effect of MIC-1 was a 22% and 47% reduction in weight of mice with moderate and high 
serum levels of human MIC-1, respectively. 
 
 
	  	  
To directly show the dependence of weight loss on MIC-1, we
injected tumor-bearing mice with antibody to MIC-1. A single
injection of a monoclonal antibody to human MIC-1 (MIC-mAb)
rapidly reversed the weight loss (Figs. 1b,c and 2a and Supplementary
Fig. 1 online) without having any effect on tumor size. Injecting
tumor-bearing mice with polyclonal sheep antibody to MIC-1 (MIC-
pAb) similarly reversed weight loss (data not shown). The magnitude
and duration of the reversal of MIC-1–induced weight loss was
proportional to the amount of MIC-mAb administered. Injection of
1 mg of MIC-mAb led to a peak weight gain of 14%, completely
reversing tumor-induced weight loss, with a duration of 17 d (Fig. 1c,
Supplementary Fig. 1). Furthermore, twice daily s.c. administra-
tion of increasing doses of human MIC-1 to normal BALB/c mice
resulted in a dose-dependent weight loss (Supplementary Fig. 2
online). Treatment with human MIC-1 (20 mg/day) resulted in
marked weight loss that could also be reversed by MIC-pAb but not
control sheep IgG (CON-pAb) (Fig. 1g). These data indicate that the
weight loss induced by MIC-1–expressing tumors is specifically
mediated by MIC-1.
MIC-1–induced weight loss is due to reduced food intake
To more specifically characterize the nature of the weight loss induced
by MIC-1–expressing tumors, we determined the changes in fat and
lean-tissue mass (Fig. 1e). Mice bearing tumors overexpressing
MIC-1 had no remaining retroperitoneal fat and 54% and 89%
reductions in inguinal and epididymal fat depots, respectively. There
were considerable reductions in the weight of the interscapular
brown adipose tissue depot (40%) as well as the tibialis and gastro-
cnemius muscles (25% and 29%, respectively) (Fig. 1e). Dual-energy
X-ray absorptiometry (DXA) scanning data confirmed that mice with
MIC-1 tumors lost an average of 5.3 g of lean mass and 1.1 g of fat
mass compared to control mice (Fig. 1f).
Mice with DU145-cell tumors overexpressing MIC-1, that were
associated with high serum MIC-1 ate, on average, 32% less food
than control mice (Fig. 1d). Similarly, administration of recombinant
MIC-1 to BALB/c mice resulted in a marked decrease in food intake
(Fig. 1h). This hypophagia was reversed by MIC-pAb treatment,
which led to weight gain (Fig. 1h). MIC-1 also induced hypophagia
and weight loss in massively obese leptin-deficient ob/ob mice that
were injected twice daily with 10 mg of MIC-1 per 20 g of body weight
for 3 d (Supplementary Fig. 3a,b online).
Vehicle-injected BALB/c mice that were fed the same amount as
that consumed by MIC-1 injected mice (pair-fed controls), lost
slightly more weight than MIC-1–injected mice. Both groups lost
weight compared to ad libitum–fed mice (Supplementary Fig. 4a,b
online). Additionally, when injected with MIC-1, BALB/c mice actu-
ally showed a small, but significant, reduction in energy expenditure,
as determined by indirect calorimetry (Supplementary Fig. 5 online).
These data establish decreased energy intake as the sole cause of
MIC-1–induced weight loss.
This reduction in energy intake by MIC-1 tumor–bearing mice led
to substantial reductions in serum concentrations of free fatty acids,
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Figure 1 Effect of MIC-1 on mouse weight, food intake and body composition. (a) Forty-five nude mice were injected s.c. with DU145 cells expressing
human MIC-1 or empty plasmid vector and monitored for 6 weeks. The mean and s.d. of weight change were plotted against serum human MIC-1 levels.
(b) Nude mice were xenografted with DU145 cells expressing MIC-1. After 11 d, three mice per dose were given a single i.p injection of MIC-1 mAb, and
five mice were injected with control buffer (vehicle) or left untreated. The mean and s.d. of their peak weight gains over 20 days are compared to the mean
weight change in these control buffer–treated and untreated mice. (c) The mean and s.d. of the duration of the response (time to return to what their weight
was on the day of antibody injection) of the mice in b is plotted against the dose of MIC-mAb. (d) Twenty nude mice were xenografted as in b. On day 8,
when the average weight loss in the MIC-1 mice was 7%, food intake was measured for three consecutive 24-h time periods and the results expressed as
the mean and s.d. (e) Twenty nude mice were engrafted as in b. They were killed when those with MIC-1 tumors had lost approximately 18% body weight.
Selected fat and muscle compartments were dissected, removed and weighed. Total white fat represents the summed weight of inguinal, epididymal and
retroperitoneal fat depots. The results are the mean and s.d. of the specimen weight as a percent of the weight of the mouse at the day of tumor injection.
(f) Mice in e underwent DXA scanning and the results are expressed as mean and s.d. of total lean and fat mass in grams. (g) Twelve BALB/c mice were
treated twice daily s.c. with 10 mg of human MIC-1. At the start of the experiment, 50% were given a single i.p. dose of 10 mg of MIC-pAb or CON-pAb.
Mice were monitored daily and their weight is expressed as a mean and s.d. percentage of their starting weight. (h) The mean and s.d. of daily food intake
of the mice in g was monitored for three consecutive 24-h time periods. *P o 0.05, **P o 0.01, ***P o 0.001.
ART ICL ES
1334 VOLUME 13 [ NUMBER 11 [ NOVEMBER 2007 NATURE MEDICINE
©
20
07
 N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
up
  h
ttp
://
ww
w.
na
tu
re
.c
om
/n
at
ur
em
ed
ic
in
e
Johnen et al.:  Tumor-induced anorexia and weight loss are mediated by the TGF-β 
superfamily cytokine MIC-1 
Nature Medicine 13(11): 1333-1340, 2007	  
	  	  	   To directly show the dependence of weight loss on MIC-1, we injected tumor-
bearing mice with antibody to MIC-1. A single injection of a monoclonal antibody to human 
MIC-1 (MIC-mAb) rapidly reversed the weight loss (Figs. 1b,c and 2a and supplementary 
fig. 1 online) without having any effect on tumor size. Injecting tumor-bearing mice with 
polyclonal sheep antibody to MIC-1 (MICpAb) similarly reversed weight loss (data not 
shown). The magnitude and duration of the reversal of MIC-1–induced weight loss was 
proportional to the amount of MIC-mAb administered. Injection of 1 mg of MIC-mAb led to 
a peak weight gain of 14%, completely reversing tumor-induced weight loss, with a 
duration of 17 d (Fig. 1c, supplementary Fig.1) Furthermore, twice daily s.c. administration 
of increasing doses of human MIC-1 to normal BALB/c mice resulted in a dose-dependent 
weight loss (supplementary Fig 2. online). Treatment with human MIC-1 (20 g/day) 
resulted in marked weight loss that could also be reversed by MIC-pAb but not control 
sheep IgG (CON-pAb) (Fig. 1g). These data indicate that the weight loss induced by MIC-
1–expressing tumors is specifically mediated by MIC-1. 
 
MIC-1–induced weight loss is due to reduced food intake 
To more specifically characterize the nature of the weight loss induced by MIC-1–
expressing tumors, we determined the changes in fat and lean-tissue mass (Fig. 1e). Mice 
bearing tumors overexpressing MIC-1 had no remaining retroperitoneal fat and 54% and 
89% reductions in inguinal and epididymal fat depots, respectively. There were 
considerable reductions in the weight of the interscapular brown adipose tissue depot 
(40%) as well as the tibialis and gastrocnemius muscles (25% and 29%, respectively) 
(Fig. 1e). Dual-energy X-ray absorptiometry (DXA) scanning data confirmed that mice with 
MIC-1 tumors lost an average of 5.3 g of lean mass and 1.1 g of fat mass compared to 
control mice (Fig. 1f). 
 Mice with DU145-cell tumors overexpressing MIC-1, that were associated with high 
serum MIC-1 ate, on average, 32% less food than control mice (Fig. 1d). Similarly, 
administration of recombinant MIC-1 to BALB/c mice resulted in a marked decrease in food 
intake (Fig. 1h). This hypophagia was reversed by MIC-pAb treatment, which led to weight 
gain (Fig. 1h). MIC-1 also induced hypophagia and weight loss in massively obese leptin-
deficient ob/ob mice that were injected twice daily with 10 g of MIC-1 per 20 g of body 
weight for 3 d (supplemtary Fig. 3a,b online). 
 Vehicle-injected BALB/c mice that were fed the same amount as that consumed by 
triglycerides, glucose, glucagon, leptin and insulin-like growth factor-1
(IGF-1; Supplementary Table 1 online), which is consistent with the
loss of lean and fat mass by these mice. Changes in circulating IGF-1
abundance suggested that the hypothalamopituitary somatotropic axis
was inhibited, which was confirmed by the reduction in growth
hormone–releasing hormone mRNA expression in the brains of
mice with MIC-1 tumors (Fig. 2c,d). Although lowered serum
IGF-1 levels may contribute to some of the effects of MIC-1, notably
the loss of lean tissues15, this change cannot account for the fat loss
observed in MIC-1–treated mice, because congenic mice with low
serum IGF-1 levels have significantly elevated body fat16.
MIC-1 tumor–bearing mice also showed a substantial reduction in
serum leptin abundance, despite having concurrent hypophagia
(Supplementary Table 1). This suggests that MIC-1 overrides the
orexigenic effects of lowered serum leptin levels and is consistent with
our observation that leptin-deficient ob/obmice also show hypophagia
and weight loss in response to MIC-1.
Prostate cancer weight loss correlates with serum MIC-1 level
To determine the relevance of MIC-1 with regard to anorexia and
weight loss in humans, we measur d serum MIC-1 lev ls in a
previously characterized cohort of individuals with advanced prostate
cancer, in whom high serum IL-6 had been associated with cachexia17.
Among patients with advanced cancer, serum MIC-1 was significantly
higher in individuals with cachexia than in those without cachexia
(12,416 ± 10,235 pg/ml versus 3,265 ± 6,370 pg/ml (mean ± s.d.);
P o 0.0001; Mann-Whitney U-test), as was serum IL-6
(33.8 ± 64.2 pg/ml versus 7.8 ± 3.4 pg/ml, Po 0.002; Mann-Whitney
U-test). Serum MIC-1 was weakly, but significantly, positively corre-
lated with serum IL-6 levels (r ¼ 0.2949, Po 0.04; linear regression).
In addition, as indicated by single and multivariate logistic regression,
both serum MIC-1 and serum interleukin-6 (IL-6) abundances were
independent predictors of the presence of cancer-induced cachexia
(univariate logistic regression: P ¼ 0.0002 and P o 0.0001, respec-
tively; multivariate logistic regression, P ¼ 0.0017 and P ¼ 0.0005,
respectively). However, the best objective and quantifiable measure
of anorexia and cachexia is weight loss. Serum MIC-1 abundance
was significantly associated with the degree of prostate cancer–
associated weight loss (Fig. 2e; P ¼ 0.0087, r ¼ 0.419, linear
regression), whereas serum IL-6 showed no such relationship
(Fig. 2f; P ¼ 0.9292; linear regression).
To assess the possibility that serum MIC-1 estimation may be a
useful predictor of prostate cancer–associated anorexia and weight
loss, we compared, by receiver operator curve analysis, the serum
marker currently used (IL-6) with serum MIC-1 measured at cancer
diagnosis. Serum MIC-1 abundance significantly outperformed IL-6
as a predictor of cancer-associated weight loss (area under the curve
(AUC) of 0.6829 for MIC-1 versus 0.3505 for IL-6; P ¼ 0.0046). To
put this value into context, the receiver operator curve analysis of the
most widely used serum marker for the diagnosis of prostate cancer,
prostate-specific antigen, has an AUC of 0.678 (95% onfidence
interval, 0.666–0.689)18. Consequently, serum MIC-1 measurement
may prove useful for the prediction of anorexia and weight loss
associated with prostate cancer and may also identify those individuals
who might benefit from any future therapy designed to reduce serum
MIC-1 abundance.
Serum MIC-1 level is correlated with BMI in chronic renal failure
Chronic renal failure, like advanced cancer, is associated with anorexia,
weight loss and cachexia. Weight loss and a lowered body mass index
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Figure 2 Effect of MIC-1 on body weight in mice and in humans with advanced prostate cancer. (a) Representative photograph of a nude mouse xenografted
with DU145 cells transfected with empty vector (A), DU145 cells overexpressing MIC-1–14 d post xenografting (B) or a mouse treated like mouse B but
given 1 mg MIC-mAb i.p. 9 d earlier (C). Arrow designates site of tumor growth. (b) Mean and s.d. of body weight of 40 nude mice xenografted with MIC-1
overexpressing or control tumors. (c,d) Emulsion autoradiographs of in situ hybridization for growth hormone–releasing hormone mRNA in the ARC of a
control tumor mouse (c) and a MIC-1 expressing tumor mouse (d). Analysis of silver grain density over individual neurons indicates a reduction from
100 ± 8% of control to 71 ± 9% of control (P ¼ 0.0343) in the MIC-1 tumor mice. ARC, arcuate hypothalamic nuclei; 3V, third ventricle. Scale bar, 40 mm.
(e,f) Correlation between weight change and serum levels of MIC-1 (e, P ¼ 0.0087; r ¼ 0.419) or IL-6 (f, P ¼ 0.9292; r ¼ 0.02) in individuals with
advanced prostate cancer.
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MIC-1 injected mice (pair-fed controls), lost slightly more weight than MIC-1–injected 
mice. Both groups lost weight compared to ad libitum–fed mice (supplementary Fig 4. A,b 
online). Additionally, when injected with MIC-1, BALB/c mice actually showed a small, but 
significant, reduction in energy expenditure, as determined by indirect calorimetry 
(supplementary Fig 5. online). These data establish decreased energy intake as the sole 
cause of MIC-1–induced weight loss. 
 This reduction in energy intake by MIC-1 tumor–bearing mice led to substantial 
reductions in serum concentrations of free fatty acids, triglycerides, glucose, glucagon, 
leptin and insulin-like growth factor-1 (IGF-1; supplementary Table 1. online), which is 
consistent with the loss of lean and fat mass by these mice. Changes in circulating IGF-1 
abundance suggested that the hypothalamopituitary somatotropic axis was inhibited, 
which was confirmed by the reduction in growth hormone–releasing hormone mRNA 
expression in the brains of mice with MIC-1 tumors (Fig. 2c,d). Although lowered serum 
IGF-1 levels may contribute to some of the effects of MIC-1, notably the loss of lean 
tissues15, this change cannot account for the fat loss observed in MIC-1–treated mice, 
because congenic mice with low serum IGF-1 levels have significantly elevated body fat16. 
 MIC-1 tumor–bearing mice also showed a substantial reduction in serum leptin 
abundance, despite having concurrent hypophagia (supplementary Table 1,). This 
suggests that MIC-1 overrides the orexigenic effects of lowered serum leptin levels and is 
consistent with our observation that leptin-deficient ob/ob mice also show hypophagia and 
weight loss in response to MIC-1. 
 
Prostate cancer weight loss correlates with serum MIC-1 level 
To determine the relevance of MIC-1 with regard to anorexia and weight loss in humans, 
we measured serum MIC-1 levels in a previously characterized cohort of individuals with 
advanced prostate cancer, in whom high serum IL-6 had been associated with cachexia17. 
Among patients with advanced cancer, serum MIC-1 was significantly higher in individuals 
with cachexia than in those without cachexia (12,416  10,235 pg/ml versus 3,265  
6,370 pg/ml (mean  s.d.); P < 0.0001; Mann-Whitney U-test), as was serum IL-6 (33.8 
 64.2 pg/ml versus 7.8  3.4 pg/ml, P < 0.002; Mann-Whitney U-test). Serum MIC-1 
was weakly, but significantly, positively correlated with serum IL-6 levels (r = 0.2949, P < 
0.04; linear regression). In addition, as indicated by single and multivariate logistic 
regression, both serum MIC-1 and serum interleukin-6 (IL-6) abundances were 
independent predictors of the presence of cancer-induced cachexia (univariate logistic 
regression: P = 0.0002 and P < 0.0001, respectively; multivariate logistic regression, P = 
0.0017 and P = 0.0005, respectively). However, the best objective and quantifiable 
measure of anorexia and cachexia is weight loss. Serum MIC-1 abundance was 
significantly associated with the degree of prostate cancer–associated weight loss (Fig. 2e; 
P = 0.0087, r = 0.419, linear regression), whereas serum IL-6 showed no such 
relationship (Fig. 2f; P = 0.9292; linear regression). 
 To assess the possibility that serum MIC-1 estimation may be a useful predictor of 
prostate cancer–associated anorexia and weight loss, we compared, by receiver operator 
curve analysis, the serum marker currently used (IL-6) with serum MIC-1 measured at 
cancer diagnosis. Serum MIC-1 abundance significantly outperformed IL-6 as a predictor of 
cancer-associated weight loss (area under the curve (AUC) of 0.6829 for MIC-1 versus 
0.3505 for IL-6; P = 0.0046). To put this value into context, the receiver operator curve 
analysis of the most widely used serum marker for the diagnosis of prostate cancer, 
prostate-specific antigen, has an AUC of 0.678 (95% confidence interval, 0.666–0.689)18. 
Consequently, serum MIC-1 measurement may prove useful for the prediction of anorexia 
and weight loss associated with prostate cancer and may also identify those individuals 
who might benefit from any future therapy designed to reduce serum MIC-1 abundance. 
 
Serum MIC-1 level is correlated with BMI in chronic renal failure 
Chronic renal failure, like advanced cancer, is associated with anorexia, weight loss and 
cachexia. Weight loss and a lowered body mass index (BMI) are also strong predictors of 
mortality in end-stage renal failure19. We examined the relationship between BMI and 
serum MIC-1 level in a cohort of 381 individuals with end-stage renal failure20. We found 
that individuals who died during the study period (up to 3 years) had a significantly lower 
BMI (26.17  5.63; 266 (mean  s.d.; n), 23.15  4.92; 104: P < 0.0001; unpaired t-
test). Serum MIC-1 levels determined in pre-dialysis samples obtained at study entry were 
significantly and inversely correlated with BMI, such that increasing serum MIC-1 levels 
were associated with lower BMI (P = 0.0003; r = 0.189; linear regression). This suggests 
that in chronic renal failure, as in cancer, elevated MIC-1 may contribute to weight loss. 
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Transgenic mice overexpressing MIC-1 are smaller and eat less 
To estimate the effects of long-term elevated MIC-1, we examined C57/BL6 transgenic 
mice that overexpressed MIC-1 under the control of the macrophage-specific colony-
stimulating factor-1 receptor promoter (fmsMIC-1 mice) (supplementary Fig. 6 online). 
Although similar in weight to wild-type controls in the first 48 h after birth (Fig. 3a), by 21 
days of age, both male and female fmsMIC-1 mice weighed 18% less than sex-matched 
wild-type littermates (Fig. 3a) and ate less in absolute terms (Fig. 3b). Like mice acutely 
treated with MIC-1, male and female fmsMIC-1 mice had lower amounts of fat in all 
measured depots (Fig. 3c,d). Overall, the data from the transgenic mice overexpressing 
MIC-1 is broadly consistent with mice acutely treated with this cytokine. 
 
 
	  	  	  
Systemically administered MIC-1 activates hypothalamic neurons 
The major regulatory centers for appetite and weight control are in the hypothalamus, 
parts of which have a semipermeable blood-brain barrier, potentially allowing for direct 
interaction with blood-borne mediators21. To determine whether MIC-1 might exert its 
effect directly on the brain, we injected mice intraperitoneally (i.p.) with human MIC-1 and 
examined the brain expression pattern of the immediate-early oncogene c-fos22. There was 
significantly increased c-fos immunoreactivity in the arcuate (ARC; P = 0.0036) and 
paraventricular nuclei (PVN; P = 0.001), implicating the neurons in these nuclei as  
(BMI) are also strong predictors of mortality in end-stage renal
failure19. We examined the relationship between BMI and serum
MIC-1 level in a cohort of 381 individuals with end-stage renal
failure20. We found that individuals who died during the study period
(up to 3 years) had a significantly lower BMI (26.17 ± 5.63; 266 (mean
± s.d.; n), 23.15 ± 4.92; 104: P o 0.0001; unpaired t-test). Serum
MIC-1 levels determined in pre-dialysis samples obtained at study
entry were significantly and inversely correlated with BMI, such
that increasing serum MIC-1 levels were associated with lower BMI
(P ¼ 0.0003; r ¼ 0.189; linear regression). This suggests that in
chronic renal failure, as in cancer, elevated MIC-1 may contribute
to weight loss.
Transgenic mice overexpressing MIC-1 are smaller and eat less
To estimate the effects of long-term elevated MIC-1, we examined
C57/BL6 transgenic mice that overexpressed MIC-1 under the control
of the macrophage-specific colony-stimulating factor-1 receptor pro-
moter (fmsMIC-1 mice) (Supplementary Fig. 6 online). Although
similar in weight to wild-type controls in the first 48 h after birth
(Fig. 3a), by 21 days of age, both male and female fmsMIC-1 mice
weighed 18% less than sex-matched wild-type littermates (Fig. 3a)
and ate less in absolute terms (Fig. 3b). Like mice acutely treated with
MIC-1, male and female fmsMIC-1 mice had lower amounts of fat in
all measured depots (Fig. 3c,d). Overall, the data from the transgenic
mice overexpressing MIC-1 is broadly consistent with mice acutely
treated with this cytokine.
Systemically administered MIC-1 activates hypothalamic neurons
The major regulatory centers for appetite and weight control are in the
hypothalamus, parts of which have a semipermeable blood-brain
barrier, potentially allowing for direct interaction with blood-borne
mediators21. To determine whether MIC-1 might exert its effect
directly on the brain, we injected mice intraperitoneally (i.p.) with
human MIC-1 and examined the brain expression pattern of the
immediate-early oncogene c-fos22. There was significantly increased
c-fos immunoreactivity in the arcuate (ARC; P ¼ 0.0036) and
paraventricular nuclei (PVN; P ¼ 0.001), implicating the neurons in
these nuclei as downstream mediators of MIC-1 action (Supplemen-
tary Fig. 7a–d online). The area postrema (AP) (Supplementary
Fig. 7e,f) also showed a significant increase in the number of
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Figure 3 Effect of prolonged action of MIC-1. (a) The weight of male and
female fmsMIC-1 transgenic mice and their matched wild-type (WT)
littermates was measured after birth (0–48 h, n ¼ 76), at 3 (n ¼ 36) and
8–9 weeks (n ¼ 40) of age. The weight has been normalized for sex and
presented as the mean and s.d. (b) Mean and s.d. of daily food intake over
three consecutive 24-h time periods on 8-week-old male and female
fmsMIC-1 and matched WT syngeneic control mice. (c,d) Five male and
five female fmsMIC-1 transgenic and four male and five female syngeneic
control mice were killed at 52–54 d of age. Fat depots and tibialis and
gastrocnemius muscles were dissected, and weighed as in Figure 1e
from five male and five female fmsMIC-1 transgenic and four male and
five female syngeneic control mice. The results are expressed separately
for females (c) and males (d) as the mean and s.d. and are normalized for
body weight. (e) A representative brain section from a mouse that received
a unilateral injection of AAV overexpressing human MIC-1, which is stained with MIC-1 mAb. (f) A higher magnification of AAV–MIC-1–expressing
hypothalamus shows the neuronal specificity of MIC-1 expression, examples of which are denoted by arrowheads. Scale bar, 40 mm. (g) Weight was
monitored in 12 mice, half of which received a unilateral hypothalamic injection of AAV–MIC-1 and the other half control AAV vector. Mice were weighed
daily and the results are plotted as mean ± s.e.m. *P o 0.05, **P o 0.01, ***P o 0.001.
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downstream mediators of MIC-1 action (supplementary Fig. 7a-d online). The area 
postrema (AP) (supplementary Fig 7e,f) also showed a significant increase in the number 
of c-fos–positive neurons (P = 0.0014), suggesting a potential role for this brainstem 
nucleus in the response to MIC-1. 
 These findings suggest that the central effect of MIC-1 is directed at the ARC, the 
major center for appetite control. Projections from the ARC reach other hypothalamic 
nuclei such as the paraventricular nuclei from which connections are formed with brain 
stem areas including the area postrema, by which they specifically modulate vagal 
sympathetic nervous system activity23. However, direct MIC-1 activation of the area 
postrema cannot be excluded. The lack of any change in c-fos activation in the nucleus 
tractus solitaris (NTS) (data not shown) suggests that afferent signals originating from the 
periphery via the vagus nerve are not involved in mediating MIC-1 effects. 
 
Hypothalamic overexpression of MIC-1 induces weight loss 
To further demonstrate that MIC-1 mediates weight loss via hypothalamic effects, we 
induced MIC-1 overexpression by direct unilateral injection of adeno-associated virus 
(AAV) carrying the MIC-1 gene, into the ARC. Immunohistochemistry in these mice 
demonstrates expression of human MIC-1 by cells in the ARC (Fig. 3e,f), and it is notable 
that these mice rapidly lost weight (Fig. 3g). Marked MIC-1–induced weight loss (21%) 
was accompanied by a decrease in food ingestion to 83% that of mice injected with empty 
AAV (P = 0.04). 
 
Systemic MIC-1 acts on the ARC through the TGF-β RII 
TGF-β superfamily proteins, such as MIC-1, bind to and act through a highly conserved 
receptor superfamily consisting of four distinct type II (RII) and seven distinct type I 
receptors (RI). Upon ligand binding, the RII transphosphorylates serine residues in the 
cytoplasmic domain of RI. This triggers a signaling cascade that involves both Smad and 
non-Smad regulatory pathways. 
       Immunohistochemistry with antibodies to different RII receptors showed that only the 
TGF-β RII colocalized with c-fos in the hypothalami of mice injected with MIC-1 (Fig. 4a,b). 
To determine whether TGF-β RII formed part of the MIC-1–binding receptor complex, we 
used unilateral hypothalamic injection of blocking antibodies to this receptor. Twenty four 
hours after this hypothalamic injection, we injected these mice i.p. with 10 g of MIC-1. 
Thirty minutes later the mice were killed and their brains examined for hypothalamic c-fos 
expression. As determined by immunohistochemistry, nuclear c-fos expression was 
inhibited on the side injected with the TGF-β RII antibody but not on the contralateral side 
(Fig. 4c–e). Notably, injection of blocking antibodies directed at the RII of bone 
morphogenetic protein (BMP) or at the leptin receptor did not result in inhibition of MIC-1–
induced c-fos expression (Fig. 4f–h). Thus, TGF-β RII is likely to form part of the complex 
through which MIC-1 exerts its effect in the hypothalamus. 
	  
c-fos–positive neurons (P ¼ 0.0014), suggesting a potential role for
this brainstem nucleus in the response to MIC-1.
These findings suggest that the central effect of MIC-1 is directed at
the ARC, the major center for appetite control. Projections from the
ARC reach other hypothalamic nuclei such as the paraventricular
nuclei from which connections are formed with brain stem areas
including the area postrema, by which they specifically modulate vagal
sympathetic nervous system activity23. However, direct MIC-1 activa-
tion of the area postrema cannot be excluded. The lack of any change
in c-fos activation in the nucleus tractus solitaris (NTS) (data not
shown) suggests that afferent signals originating from the periphery
via the vagus nerve are not involved in mediating MIC-1 effects.
Hypothalamic overexpression of MIC-1 induces weight loss
To further demonstrate that MIC-1 mediates weight loss via hypotha-
lamic effects, we induced MIC-1 overexpression by direct unilateral
injection of adeno-associated virus (AAV) carrying the MIC-1 gene,
into the ARC. Immunohistochemistry in these mice demonstrates
expression of human MIC-1 by cells in the ARC (Fig. 3e,f), and it is
notable that these mice rapidly lost weight (Fig. 3g). Marked MIC-
1–induced weight loss (21%) was accompanied by a decrease in food
ingestion to 83% that of mice injected with empty AAV (P ¼ 0.04).
Systemic MIC-1 acts on the ARC through the TGF-b RII
TGF-b superfamily proteins, such as MIC-1, bind to and act
through a highly conserved receptor superfamily consisting of
four distinct type II (RII) and seven distinct type I receptors
(RI). Upon ligand binding, the RII transphosphorylates serine
residues in the cytoplasmic domain of RI. This triggers a signaling
cascade that involves both Smad and non-Smad regulatory pathways.
Immunohistochemistry with antibodies to different RII receptors
showed that only the TGF-b RII colocalized with c-fos in the
hypothalami of mice injected with MIC-1 (Fig. 4a,b). To determine
whether TGF-b RII formed part of the MIC-1–binding receptor
complex, we used unilateral hypothalamic injection of blocking
antibodies to this receptor. Twenty four hours after this hypothalamic
injection, we injected these mice i.p. with 10 mg of MIC-1. Thirty
minutes later the mice were killed and their brains examined for
hypothalamic c-fos expression. As determined by immunohistochem-
istry, nuclear c-fos expression was inhibited on the side injected with
the TGF-b RII antibody but not on the contralateral side (Fig. 4c–e).
Notably, injection of blocking antibodies directed at the RII of bone
morphogenetic protein (BMP) or at the leptin receptor did not result
in inhibition of MIC-1–induced c-fos expression (Fig. 4f–h). Thus,
TGF-b RII is likely to form part of the complex through which MIC-1
exerts its effect in the hypothalamus.
To probe the mechanisms by which MIC-1 induces its downstream
effects, we used immunohistochemistry to examine the hypothalamus
of mice injected i.p. with 10 mg of MIC-1, and when we did not see a
response, we increased the dose to 100 mg. Using antibodies specific
for the phosphorylated forms of Smad-2, Smad-3 and Smads 1, 5 and
8, we could not detect any substantial increase in phospho-Smad
staining in the MIC-1–treated mice, suggesting that these pathways are
not used or that the constitutive activation of these pathways masks
any significant increase in Smad phosphorylation. However, MIC-1,
but not control buffer, induced phosphorylation of extracellular signal–
regulated kinase 1/2 in the ARC (Supplementary Fig. 8a–c online),
suggesting that MIC-1 may mediate some of its effects via this pathway.
MIC-1 modulates ARC NPY, POMC mRNA and Stat3
As measured by in situ hybridization, MIC-1 injection reduced the
level of neuropeptide Y mRNA expression in the ARC by 34% and
increased pro-opiomelanocortin (POMC) mRNA levels by 47%,
consistent with a reduced feeding drive (Fig. 5). This upregulation
of the POMC anorexigenic and downregulation of neuropeptide Y
orexigenic pathways is similar to the pattern observed in leptin-treated
a
fe g h
b c d
Figure 4 MIC-1 receptor identification. Mice were injected i.p. with 100 mg of MIC-1 and their brains isolated. (a) Sections were double labeled with
antibodies for TGF-b RII and c-fos (marker of cell activation). Scale bar, 25 mm. (b) Higher magnification of the area marked in a. Cells are stained with
antibody only to TGF-b RII (purple arrowhead), and cell nuclei are stained with antibody to c-fos (black arrowhead). Selected double labeled cells are marked
with white arrowheads. Scale bar, 5 mm. (c–e) Mice were given an intrahypothalamic injection of antibody to TGF-b RII, on the right, as indicated in c,
followed by an i.p. injection of MIC-1 24 h later. (c) Sections were then labeled with a rabbit antibody to c-fos as well as antibody to goat IgG to detect the
goat antibody to TGF-b RII that had been directly injected into the hypothalamus. Scale bar, 40 mm (d,e) High-power views of the areas in c. Nuclear c-fos
staining is eliminated only on the side of injection of the antibody to TGF-b RII (e), but staining of TGF-b RII is clearly visible (purple arrow). Both on the
side of intrahypothalamic injection of TGF-b RII antibody but distant from the injection site, and on the contralateral side, is c-fos staining (black arrow).
Scale bar, 25 mm. (f,g,h) Unilateral ARC injection of antibody to TGF-b RII (f), but not antibody to the leptin receptor (g) or BMP RII (h), blocks MIC-1–
induced c-fos staining. With antibody to TGF-b RII (f), this inhibition is confined to the side of injection (right). Scale bar, 40 mm. D3V, dorsal third ventricle;
fr, frasciculus retroflexus.
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 To probe the mechanisms by which MIC-1 induces its downstream effects, we used 
immunohistochemistry to examine the hypothalamus of mice injected i.p. with 10 µg of 
MIC-1, and when we did not see a response, we increased the dose to 100 µg. Using 
antibodies specific for the phosphorylated forms of Smad-2, Smad-3 and Smads 1, 5 and 
8, we could not detect any substantial increase in phospho-Smad staining in the MIC-1–
treated mice, suggesting that these pathways are not used or that the constitutive 
activation of these pathways masks any significant increase in Smad phosphorylation. 
However, MIC-1, but not control buffer, induced phosphorylation of extracellular signal–
regulated kinase 1/2 in the ARC (supplementary Fig. 8a-c online), suggesting that MIC-1 
may mediate some of its effects via this pathway. 
 
MIC-1 modulates ARC NPY, POMC mRNA and Stat3 
As measured by in situ hybridization, MIC-1 injection reduced the level of neuropeptide Y 
mRNA expression in the ARC by 34% and increased pro-opiomelanocortin (POMC) mRNA 
levels by 47%, consistent with a reduced feeding drive (Fig. 5). This upregulation of the 
POMC anorexigenic and downregulation of neuropeptide Y orexigenic pathways is similar to 
the pattern observed in leptin-treated mice. Because of this similarity, we also probed the 
hypothalamus with antibodies to phosphorylated signal transducer and activator of 
transcription-3 (P-Stat3), a central molecule activated via the leptin receptor signaling 
pathway (Fig. 6). We found that MIC-1–induced upregulation of P-Stat3 in neurons in the 
lateral ARC and ventromedial hypothalamus (Fig. 6b). Notably, the pattern of P-Stat3 
staining in MIC-1–treated mice was different from that induced by leptin injection, with the 
majority of P-Stat3–positive neurons being present in the lateral ARC compared to the 
dorsal ARC with leptin injection (Fig. 6a). Thus, MIC-1 and leptin induce P-Stat3 in 
different subsets of ARC neurons, suggesting that they induce their effects through distinct 
pathways. Indeed, injection of MIC-1 into leptin receptor–deficient db/db mice produced P-
Stat3 staining in the ARC comparable to that seen in wild-type MIC-1–injected mice (Fig. 
6d), showing that MIC-1 does not act through the leptin receptor. 
 
 
	  	  	  	  	  	   	  	  	  
mice. Because of this similarity, we also probed the hypothalamus
with antibodies to phosphorylated signal transducer and activator
of transcription-3 (P-Stat3), a central molecule activated via the
leptin receptor signaling pathway (Fig. 6). We found that MIC-1–
induced upregulation of P-Stat3 in neurons in the lateral ARC and
ventromedial hypothalamus (Fig. 6b). Notably, the pattern of P-Stat3
staining in MIC-1–treated mice was different from that induced by
leptin injection, with the majority of P-Stat3–positive neurons being
present in the lateral ARC compared to the dorsal ARC with leptin
injection (Fig. 6a). Thus, MIC-1 and leptin induce P-Stat3 in different
subsets of ARC neurons, suggesting that they induce their effects
through distinct pathways. Indeed, injection of MIC-1 into leptin
receptor–deficient db/db mice produced P-Stat3 staining in the ARC
comparable to that seen in wild-type MIC-1–injected mice (Fig. 6d),
showing that MIC-1 does not act through the leptin receptor.
To identify the MIC-1–induced, P-Stat3–positive neurons, we
carried out in situ hybridization for NPY (the gene encoding
neuropeptide Y, Fig. 5g,h) or immunohistochemistry for
a-melanocyte–stimulating hormone (a-MSH) (Fig. 5e,f), a biologi-
cally active processed product of POMC, along with immunohisto-
chemistry and immunofluorescence for P-Stat3 (Fig. 5e–h). This
demonstrates that MIC-1–induced P-Stat3–positive neurons colocalize
with a-MSH–staining (Fig. 5e,f) and NPY– (Fig. 5g,h) expressing
neurons. This identifies neuropeptide Y and POMC neurons as the
a
e f g h
b c d
MIC-1 MIC-1 Leptin Control
Figure 6 MIC-1, injected systemically or locally, induces Stat3 phosphorylation in the hypothalamus, even in db/db mice. (a–d) Wild-type BALB/c (a–c) or
leptin receptor–deficient db/db (d) mice were injected i.p. with either 100 mg leptin (a), 100 mg human MIC-1 (b,d) or control buffer (c). (e–h) Wild-type
BALB/c mice also received direct unilateral injection into the hypothalamus of either 1 mg of human MIC-1 (e,f), leptin (g) or control buffer (h). Either
20 (e–h) or 30 min (a–d) after injection, mice were perfused, and their brain sections were stained with antibody to P-Stat3. Scale bars: a–d,f–h,
40 mm; e, 100 mm.
a b c d
e f g h
Figure 5 MIC-1 induces alteration in expression of neuropeptide Y and POMC in neurons expressing phosphorylated Stat3. (a–d) BALB/c mice were injected
i.p. with either control buffer (a,c) or 10 mg human MIC-1 (b,d). In situ hybridization was performed on brain sections isolated 1 h after injection to measure
expression of neuropeptide Y (a,b) and POMC mRNA (c,d). Expression levels quantified in the ARC relative to control-injected mice indicated a significant
downregulation of neuropeptide Y mRNA from 100 ± 13.3% to 66 ± 6.1% of control (P ¼ 0.0272) and an upregulation of POMC mRNA from 100 ± 7.6%
to 147 ± 10.5% of control (P ¼ 0.0061). Scale bar, 40 mm. (a-e,g). Different wild-type BALB/c mice were injected i.p. with 100 mg of human MIC-1,
and 30 min after injection the mice were killed and brain sections stained with antibody to P-Stat3 together with immunofluorescent antibody to a-MSH
(e) to demonstrate colocalization of P-Stat3 (red) and a-MSH (green) within individual cells (arrows in f). Boxed area in e is enlarged in f. In situ
hybridization for NPYY mRNA combined with immunohistochemistry for P-Stat-3 shows their colocalization (arrowheads) (g,h). Boxed area in g is enlarged
in h. Scale bar (f,h), 25 mm.
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 To identify the MIC-1–induced, P-Stat3–positive neurons, we carried out in situ 
hybridization for NPY (the gene encoding neuropeptide Y, Fig. 5g,h) or 
immunohistochemistry for -melanocyte–stimulating hormone ( -MSH) (Fig. 5e,f), a 
biologically active processed product of POMC, along with immunohistochemistry and 
immunofluorescence for P-Stat3 (Fig. 5e–h). This demonstrates that MIC-1–induced P-
Stat3–positive neurons colocalize with -MSH–staining (Fig. 5e,f) and NPY– (Fig. 5g,h) 
expressing neurons. This identifies neuropeptide Y and POMC neurons as the major class 
of targets for MIC-1, and it suggests that the reduced food intake leading to weight loss 
results from altered neuropeptide Y and -MSH production. Consistently with the c-fos 
data (supplementary Fig. 7b) the majority of these P-Stat3/neuropeptide Y– and P-Stat3/
-MSH–positive neurons represent a different subset from the ones activated by leptin, 
suggesting a potential new pathway through which MIC-1 could regulate appetite. 
 
Direct injection of MIC-1 into ARC also activates Stat3 
To further demonstrate that MIC-1 acts directly on the ARC, we performed direct unilateral 
injection of MIC-1, leptin or control buffer into the ARC (Fig. 6e–h). Both MIC-1 (Fig. 6e,f) 
and leptin (Fig. 6g) clearly induced activation of P-Stat3 in the ARC at 20 min after 
injection in a pattern similar to that seen with systemic administration. MIC-1 injection 
induced the phosphorylation of Stat3 in neurons in the lateral ARC and the dorsal 
ventromedial hypothalamic nucleus (VMHDM) (Fig. 6e,f). In contrast, leptin injection 
activated the Stat3 pathway in neurons of the dorsal ARC, the dorsal VMHDM and lateral 
hypothalamic area (Fig. 6g). This supports our contention that these two mediators act on 
different hypothalamus neuronal subsets. 
 
DISCUSSION 
Tumor overproduction of MIC-1 and the correlation of serum MIC-1 levels with weight loss 
(in both animal models and in individuals with prostate cancer) suggest that MIC-1 is 
involved in the pathogenesis of cancer anorexia and weight loss and is perhaps involved in 
other cachectic conditions, such as those that are associated with renal and cardiac failure. 
Although many studies describe high cytokine levels in individuals with cancer anorexia 
and cachexia, we are not aware of any studies that have shown a direct correlation of 
cytokine abundance with a degree of weight loss such as the one we have shown with 
MIC-1. This relationship, as well as our finding that MIC-1 acts on TGF-β RII receptors in 
hypothalamic neurons and thereby may decrease appetite, suggest that MIC-1 is a key 
inducer of cancer-related anorexia and weight loss. Additionally, the reversal of weight loss 
caused by treatment with antibodies to MIC-1 raises the possibility that therapeutic 
antibodies may be used to treat this serious disorder. MIC-1 induces hypophagia and 
affects the major hypothalamic regulators of food intake and energy homeostasis, 
neuropeptide Y and POMC-derived -MSH. Although MIC-1 triggers effects similar to those 
induced by leptin, such as anorexia, weight loss, a decrease in hypothalamic neuropeptide 
Y and an increase in POMC expression, there are differences in the subset of neuropeptide  
mice. Because of this similarity, we also probed the hypothalamus
with antibodies to phosphorylated signal transducer and activator
of transcription-3 (P-Stat3), a central molecule activated via the
leptin receptor signaling pathway (Fig. 6). We found that MIC-1–
induced upregulation of P-Stat3 in neurons in the lateral ARC and
ventromedial hypothalamus (Fig. 6b). Notably, the pattern of P-Stat3
staining in MIC-1–treated mice was different from that induced by
leptin injection, with the majority of P-Stat3–positive neurons being
present in the lateral ARC compared to the dorsal ARC with leptin
injection (Fig. 6a). Thus, MIC-1 and leptin induce P-Stat3 in different
subsets of ARC neurons, suggesting that they induce their effects
through distinct pathways. Indeed, injection of MIC-1 into leptin
receptor–deficient db/db mice produced P-Stat3 staining in the ARC
comparable to that seen in wild-type MIC-1–injected mice (Fig. 6d),
showing that MIC-1 does not act through the leptin receptor.
To identify the MIC-1–induced, P-Stat3–positive neurons, we
carried out in situ hybridization for NPY (the gene encoding
neuropeptide Y, Fig. 5g,h) or immunohistochemistry for
a-melanocyte–stimulating hormone (a-MSH) (Fig. 5e,f), a biologi-
cally active processed product of POMC, along with immunohisto-
chemistry and immunofluorescence for P-Stat3 (Fig. 5e–h). This
demonstrates that MIC-1–induced P-Stat3–positive neurons colocalize
with a-MSH–staining (Fig. 5e,f) and NPY– (Fig. 5g,h) expressing
neurons. This identifies neuropeptide Y and POMC neurons as the
a
e f g h
b c d
MIC-1 MIC-1 Leptin Control
Figure 6 MIC-1, injected systemically or locally, induces Stat3 phosphorylation in the hypothalamus, even in db/db mice. (a–d) Wild-type BALB/c (a–c) or
leptin receptor–deficient db/db (d) mice were injected i.p. with either 100 mg leptin (a), 100 mg human MIC-1 (b,d) or control buffer (c). (e–h) Wild-type
BALB/c mice also received direct unilateral injection into the hypothalamus of either 1 mg of human MIC-1 (e,f), leptin (g) or control buffer (h). Either
20 (e–h) or 30 min (a–d) after injection, mice were perfused, and their brain sections were stained with antibody to P-Stat3. Scale bars: a–d,f–h,
40 mm; e, 100 mm.
a b c d
e f g h
Figure 5 MIC-1 induces alteration in expression of neuropeptide Y and POMC in neurons expressing phosphorylated Stat3. (a–d) BALB/c mice were injected
i.p. with either control buffer (a,c) or 10 mg human MIC-1 (b,d). In situ hybridization was performed on brain sections isolated 1 h after injection to measure
expression of neuropeptide Y (a,b) and POMC mRNA (c,d). Expression levels quantified in the ARC relative to control-injected mice indicated a significant
downregulation of neuropeptide Y mRNA from 100 ± 13.3% to 66 ± 6.1% of control (P ¼ 0.0272) and an upregulation of POMC mRNA from 100 ± 7.6%
to 147 ± 10.5% of control (P ¼ 0.0061). Scale bar, 40 mm. (a-e,g). Different wild-type BALB/c mice were injected i.p. with 100 mg of human MIC-1,
and 30 min after injection the mice were killed and brain sections stained with antibody to P-Stat3 together with immunofluorescent antibody to a-MSH
(e) to demonstrate colocalization of P-Stat3 (red) and a-MSH (green) within individual cells (arrows in f). Boxed area in e is enlarged in f. In situ
hybridization for NPYY mRNA combined with immunohistochemistry for P-Stat-3 shows their colocalization (arrowheads) (g,h). Boxed area in g is enlarged
in h. Scale bar (f,h), 25 mm.
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Y and POMC neurons activated by MIC-1. This suggests there is a more diverse functional 
network of neurons regulating different aspects of energy homeostasis than was previously 
thought. Taken together, the data in this study show that MIC-1 is a previously unknown 
central regulator of appetite and weight and is a potential target for the treatment of 
cancer anorexia and weight loss, as well as of obesity. 
 
METHODS 
 
Ethics committee approval. 
All mouse experiments were approved by the Garvan and the St. Vincent's Hospital Animal 
Ethics Committees. The human studies described were done with informed consent from 
study subjects and with the approval of either the Institutional Review Board of the 
University of Washington or the Hennepin County Medical Center/Minneapolis Medical 
Research Foundation/Hennepin Faculty Associates Human Subject Research Committee. 
 
Tumor xenograft model. 
We injected 8-week-old BALB/c nude mice s.c. on their right flanks with 5 X 106 to 7 X 106 
transfected DU145 cells in 200 ml of PBS. The DU145 cells had been transfected with 
either the pIRES2-EGFP plasmid (Clontech) containing either mature MIC-1 (MIC-1), full 
length MIC-1, a proconvertase site-deletion mutant of MIC-1 or empty vector11. Once 
tumors were visible, we measured tumor size and weighed the mice every 1–3 days for 6 
weeks. 
 We determined lean and fat mass both by DXA (Lunar Piximus II, GE Medical 
Systems) and by dissection of white and brown adipose tissue depots and tibialis and 
gastrocnemius muscles. We then expressed these weights as a proportion of the body 
weight of the mouse on the day of the tumor injection. 
 We measured food consumption by placing food into the hopper, which was 
weighed at time 0, and then we determined the amount of food consumed at 24 h 
intervals by subtracting refusal and spillage from the food put into the hopper. 
 
Arcuate hypothalamic nucleus injection of AVV–MIC-1. 
Adult male mice were anesthetized i.p. with a single dose of ketamine and xylazine (100 
mg/kg and 20 mg/kg, respectively) and placed on a Kopf stereotaxic frame (David Kopf 
Instruments). We injected 1 µl AAV–MIC-1 or control 'empty' AAV unilaterally into the ARC 
at a rate of 0.1 µl/min with a 10-µl Hamilton syringe attached to a Micro4 Micro Syringe 
Pump Controller (World Precision Instruments, Inc.). We injected for 10 min and then left 
the needle in place for a further 15 min to allow for diffusion away from the needle tip. The 
injection coordinates were as follows (distance from bregma): anterioposterior, -1.94 mm; 
mediolateral, -0.3 mm; dorsoventral, -5.8 mm; this corresponded to the ARC 
hypothalamic nucleus24, 25. We always performed the injections between 10 a.m. and 12 
p.m. 
 
Mouse intrahypothalamic injection. 
We anesthetized the mice, placed them in a Kopf stereotaxic frame and injected them 
unilaterally with a Hamilton syringe as indicated above. 
 For direct injection of cytokines, we injected adult wild-type mice with 1 µl MIC-1, 
1 µl leptin or 1 µl control solution using the following coordinates (distance from bregma): 
posterior, -1.94 mm; lateral, -0.3 mm; ventral, -5.8 mm; this corresponded to the ARC25. 
Thirty minutes after the start of injection, we killed the mice. We fixed the brains by 
perfusion and P-Stat3 neurons were identified by immunohistochemistry as indicated 
below. 
 For experiments involving the injection of TGF-β receptor antibodies, we injected 
1.5 µl of antibody (0.1 mg/ml) unilaterally into the posterior hypothalamic areas of three 
adult mice at a rate of 0.1 µl/min. The injected antibody was inhibitory goat antibody to 
TGF-β RII (R&D Systems), BMP RII (GeneTex, Inc.) or leptin receptor (Upstate). The 
needle was left in place for 10 min after injection to allow diffusion away from the injection 
site. The injection coordinates were as follows (distance from bregma): anterioposterior, -
2.3 mm; mediolateral, -0.5 mm; dorsoventral, -4.5 mm; this corresponded to the 
posterior hypothalamic area25. Twenty-four hours after TGF-β RII antibody injection, we 
injected mice i.p. with 100 µg of human MIC-1. Exactly 30 min after injection, we killed the 
mice and collected the brains for detection of c-fos and TGF-β RII immunoreactive neurons 
in the posterior hypothalamic area as described below. 
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 In an alternative experiment, we divided six adult male mice into three groups and  
 
injected the following antibodies into the ARC: 1.5 µl TGF-β RII antibody (0.1 mg/ml), 1.5 
µl BMPRII antibody (0.1 mg/ml) or 1.5 µl leptin antibody (0.1 mg/ml). The needle was left 
in place for 10 min after injection to allow for diffusion away from the injection site. The 
injection coordinates were as follows (distance from bregma): anterioposterior, -1.94 mm; 
mediolateral, -0.3 mm; dorsoventral, -5.8 mm; this corresponded to the ARC 
hypothalamic nucleus25. Twenty-four hours after antibody injection, animals were injected 
i.p. with 100 µg of human MIC-1; 30 min later, the mice were killed and brains were 
collected for detection of c-fos immunoreactivity in the ARC hypothalamic area as 
described in the supplementary methods online. 
 
Additional methods. 
Information on the generation of MIC-1-overexpressing transgenic mice, MIC-1 reagents 
and production of AAV vector engineered to express MIC-1, the determination of metabolic 
rate, respiratory exchange ratio, and physical activity, as well as details about the pair-
feeding experiment, the cancer cachexia patient cohort, immunohistochemistry and 
immunofluorescence of mouse brain, in situ hybridization, combined 
immunohistochemistry and in situ hybridization, and statistical analysis are available in the 
supplementary methods 
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